FDA critics often say that the agency is too slow in approving new cancer drugs, says Pharmalot's Ed Silverman. But a new study by researchers at nonprofit think tank Friends of Cancer Research recently published in Health Affairs shows that the median approval time for oncology drugs in the US is about half that of Europe.
Faster Than You Think
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.